Inclisiran not checked
Novartis · KJX839 · PCSK9 inhibitor
FollowEvery change as it happens, and a Monday email
Trials
20 active
35 in total · 15 in the EU
Targets
—
None known yet
What this is
- How it works
- A short strand of RNA that switches off one gene, so the body makes less of one protein.-siran: small interfering RNA WHO name stem
- How it’s given
- “Inclisiran in solution for subcutaneous injection on day 1, day 90, and day 270”In the company’s words, NCT06501443 on ClinicalTrials.gov
- Tested for
- Hypercholesterolaemia (2 trials), Acute Coronary Syndrome (2 trials), Plaque, Atherosclerotic, Coronary Heart Disease, Hypercholesterolemia, Coronary Artery Disease, Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease (ASCVD) and 5 more
- Main trialPhase 4
- “This is an open label, patient-level 1:1 randomized clinical trial in a multi-country study aiming to evaluate the real-world impact of inclisiran + Usual Care (UC) vs UC alone on LDL-C lowering, patient-reported outcomes, and healthcare resource utilization in an in-hospital population of patients, admitted during the acute setting, stabilized and before discharge, following an acute cardiovascular event.”In the company’s words, NCT06501443 on ClinicalTrials.gov
- Other names
- KJX839 · ALN-PCSSC · Leqvio · PCSK9 inhibitor · siRNA
Other drugs for Hypercholesterolaemia
- ObicetrapibNewAmsterdam Pharma · Phase 3
- Laroprovstat/rosuvastatinAstraZeneca · Phase 3
- LaroprovstatAstraZeneca · Phase 3
- FDC laroprovstat/RosuvastatinAstraZeneca · Phase 3
- EnlicitideMerck & Co. · Phase 3
- Bempedoic acid/ezetimibeDaiichi Sankyo · Phase 3
Coming up12
- 27 NovPhase 4 trial completes · ClinicalTrials.gov
- 21 DecPhase 1 trial completes · ClinicalTrials.gov
- 30 DecPhase 4 trial completes · ClinicalTrials.gov
- 16 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 28 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 Apr 2027Phase 4 trial completes · ClinicalTrials.gov
- 10 May 2027Phase 3 trial completes · ClinicalTrials.gov
- 3 Feb 2028Phase 3 trial completes · ClinicalTrials.gov
- 29 Feb 2028Phase 4 trial completes · ClinicalTrials.gov
- 21 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
- 21 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
- 16 Apr 2029Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 17 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT07102628
- 17 NovCompletion date moved: 2027-02-11 to 2027-01-16 · ClinicalTrials.gov NCT07102628
Trials35
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 27 Nov 2026 | LATAM LOWERS LDL-C | |
| Phase 4Active, not recruiting | 30 Dec 2026 | Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction | |
| Phase 4Active, not recruiting | 30 Apr 2027 | Inclisiran Effectiveness in China: a Pragmatic Randomized Trial | |
| Phase 4Not yet recruiting | 29 Feb 2028 | Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia | |
| Phase 3Active, not recruiting | 9 Jun 2022 | Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C) | |
| Phase 3Active, not recruiting | 26 Oct 2026 | Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events | |
| Phase 3Active, not recruiting | 16 Jan 2027 | Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | |
| Phase 3Active, not recruiting | 10 May 2027 | Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | |
| Phase 3Active, not recruiting | 3 Feb 2028 | Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD | |
| Phase 3Recruiting | 21 Mar 2028 | Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia | |
| Phase 3Recruiting | 21 Mar 2028 | Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia | |
| Phase 3Active, not recruiting | 16 Apr 2029 | A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | |
| Phase 3Recruiting | 25 Mar 2032 | Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies | |
| Phase 2Recruiting | 28 Apr 2027 | A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia | |
| Phase 1Recruiting | 21 Dec 2026 | Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation | |
| Phase 4Completed | 11 Jun 2024 | Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia | |
| Phase 4Completed | 1 Dec 2025 | A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease. | |
| Phase 4Completed | 13 Jan 2026 | A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia | |
| Phase 3Completed | 2 Mar 2020 | A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | |
| Phase 3Completed | 13 Jan 2023 | Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support | |
| Phase 3Completed | 13 Feb 2023 | Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C | |
| Phase 3Completed | 15 Sep 2023 | A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE) | |
| Phase 3Completed | 30 Oct 2023 | Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia | |
| Phase 3Completed | 9 Nov 2023 | Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia | |
| Phase 3Completed | 2 Apr 2024 | Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. | |
| Phase 3Completed | 20 Jun 2024 | Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy. | |
| Phase 3Completed | 7 Aug 2024 | Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome | |
| Phase 2Completed | 17 Dec 2021 | An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol | |
| Phase 2Completed | 18 Apr 2022 | Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C | |
| Phase 1Completed | 18 Oct 2021 | Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C | |
| Phase 3Authorised | not given | Comparison of inclisiran or alirocumab to standard therapy in pediatric heterozygous familial hypercholesterolemia (HeFH) – the head-to-head PICOLO-FH clinical trial | |
| Phase 4Authorised | not given | The relationship of cholesterol-lowering drugs with steroid HORMONEs, bile acids, muscle morphology, vitamin D, the immune system and related diseases such as depression and osteoporosis | |
| Phase 4Authorised | not given | Implementation Study of Lipid Management of High-risk Cardiovascular Patients- Semmelweis Lipid Center for High-risk Patients | |
| Phase 4Authorised | not given | Effect of Inclisiran on LDL-C Levels and Coronary Plaque Burden Assessed by Ultra-High Resolution Photon-Counting CT Angiography | |
| Phase 4Authorised | not given | Early LDL -cholesterol reduction in patients with acute coronary syndrome: a randomized clinical trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026